Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-672-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
Carcinogenicity, mice and rats, dermal (NTP 2012, similar to OECD 451, acc. to GLP)
Carcinogenicity, mice, dermal, 80 weeks (2 times/week/50mg): not carcinogenic (Cytec, Kettering, 1982 Barkley W.) but less reliable.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- other: rats and mice
- Quality of whole database:
- Key study according to GLP, following NTP standard protocol. Thus, a klimisch score of 1 for key study.
Justification for classification or non-classification
In summary, no human relevant carcinogenic hazard can be deduced from these studies. Margnial differences observed in the NTP study are considered incidental and not test-substance related based on the arguments presented above and in the robust study summary. Thus TMPTA does not fulfil the requirement according to GHS (Regulation (EU) 1272/2008) or DPD (67/548/EEC) to be labelled as carcinogen.
Classification carcinogenicity:
GHS: no classification
DSD: no classification
Additional information
In a carcinogenicity study performed by NTP in 2012, 65 male and female mice or rats per group were dermally exposed to 0, 0.3, 1.0, and 3.0mg/kg trimethylolpropane triacrylate for 2 years. Interim kills of 5 animals per sex and group were performed after 2, 13, and 52 weeks to evaluate effects on the skin. Survival and body weight gain was unaffected by the test substance. Rats and mice of the mid and high dose groups and low dose female rats showed increased incidences of epidermal hyperplasia, hyperkeratosis, and signs of chronic inflammation (mice). Despite these local effects, no increase in skin tumors compared to control animals could be detected. No test-substance related increase in neoplastic lesions was found for male mice and female rats.
In male rats, there was a positive trend in the incidences of malignant mesothelioma (0%, 4%, 4%, 10% for 0, 0.3, 1, 3mg/kg). In all cases, they arose from the tunics around the testes. The increase was significant in animals receiving 3mg/kg, but only exceeded the recent historical control range by one tumor. In addition, this is a common spontaneous lesion of the peritoneal cavity in male F344/N rats (Hall, 1990). Because of the variability of these tumors in the historical controls and the fact that the incidence in the high dose group was only one tumor outside of the historical control range, the marginally increased incidences were considered to be equivocal evidence of carcinogenic activity of trimethylolpropane triacrylate in male rats. A recently published review by Maronpot and colleagues examined the nature of tunica vaginalis mesothelioma (TVM) responses in 21 published rat cancer bioassays. Maronpot reported that TVM induction is a male F344 rat-specific (and possibly strain-specific) event, and in the absence of other chemical-induced tumorigenesis, is likely to be irrelevant in human risk assessment. Also in contrast to rats, the tunica vaginalis in the adult human does not directly connect to the peritoneal cavity.
In female mice the increase in hepatoblastoma was not significant and not dose related (0%, 4%, 0%, 6% for control, low, mid, and high dose). Thus they are not considered to be treatment related by the registrant despite low incidences in historical control animals. 1 and 2 of 50 mid and high dose female mice developed hepatocholangiocarcinoma. This rare tumor has not been observed in concurrent and recent historical controls, but occured with a frequency of 0-4% (0-2 tumors per 50 mice) in older historical controls.
The incidences of uterine stromal polyps showed a positive trend and were significantly increased in the 3mg/kg group. The incidences of 0%, 2%, 4%, and 10% in control, low, mid, and high dose female mice exceeded recent historical control data by on tumor (0-8%), but were within older historical control data (0-16%). The incidences of uterine sarcoma was not affected by the test substance. In a publication by Davis (2012), a range of 0 -14.3% is reported in B6C3F1/N female mice for the incidence of benign stromal polyps. Endometrial stromal polyps in rodents appear as age-related lesions. Endometrial polyps that occur in women have distinctly different characteristics. Human endometrial polyps develop from both endometrial and stromal components, whereas rodent stromal polyps develop from stromal components only. Endometrial polyps in women are clearly hormone sensitive, while in rodents, these lesions do not appear to be hormonally sensitive. Based on these key differences, stromal polyps observed in rodents have at most limited, but probably no relevance to humans.
It should be noted that TMPTA was not carcinogenic on the skin of rats and mice, even though it was dermally applied at doses, which produced significant irritation and dermal injury. Although NTP absorption studies showed uptake of approximately 30% through the skin, the highest amount of TMPTA must have been present on or in the skin. Additionally, TMPTA is rapidly metabolized (most likely conjugated to glutathione in blood) and excreted via urine, so that quantification of the parent compound in blood was impossible. Considering that TMPTA is not genotoxic as discussed in the section on mutagenicity and does not accumulate in vivo, the applied doses of up to 3mg/kg b.w. are too low for tumor induction especially in non-target tissues. The observed increases in tumor incidence are marginal (1 tumor above recent historical control data), and are within historical control data obtained with a different kind of diet (NIH07). Interpretation of historical control data is also limited by the fact that no studies exist in the database, which used aceton as vehicle for dermal application. In conclusion, the increases in tumor incidences are considered incidental by the registrant and not substance related.
Studies according to other protocols:
A study was conducted to assess the carcinogenic potential of trimethylolpropane triacrylate (TMPTA) in C3H/HeJ male mice (Cytec, Kettering, 1982 Barkley W.). Therefore Groups of C3H/HeJ male mice (50/dose) received topical application of 50 mg of the test substance (5 % in white mineral oil) to shaved area of the back, twice weekly for 80 weeks. A group of solvent control and positive control (0.05% benzo(a)pyrene in mineral oil) were also maintained along with no-treatment control group in the study. Parameters evaluated included clinical signs, mortality, body weight, gross pathology and histopathological (neoplastic and non-neoplastic) examinations. The gross observations made at necropsy were dark red lesions in lungs, liver tumors, kidney haemorrhages, enlarged spleen, skin ulcers, flaky skin, enlarged and grey lymph nodes, haemorrhages in stomach, grey or yellow spots in adrenals. Non-neoplastic histopathologic lesions included ulcer, abscess, acanthosis, dysplasia, fibrosis, pigmentation, hyperkeratosis and retention cyst. In accordance with the NTP study, no skin tumors were found in treated animals. In conclusion, test substance trimethylolpropane triacrylate (TMPTA) was considered to not carcinogenic in mice.
Justification for selection of carcinogenicity via dermal route endpoint:
Two relevant studies available:
Carcinogenicity, mice and rats, dermal (NTP 2012, similar to OECD 451, acc. to GLP) identified as key study.
Carcinogenicity, mice, dermal, 80 weeks (2 times/week/50mg): not carcinogenic (Cytec, Kettering, 1982 Barkley W.) but less reliable, thus supporting study.
Carcinogenicity: via dermal route (target organ): other: skin
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
